Needs/Wishes for Innovation
Businesses looking for similar products or services There are currently no matches found. Please check back at a later time. |
New Cancer Treatment: Synthethic Hydroisobenzofurans Sustainable, synthetic hydroisobenzofurans for cancer treatment There are currently no reviews for this Innovation.
| New Cancer Treatment: Synthethic Hydroisobenzofurans
Sustainable, synthetic hydroisobenzofurans for cancer treatment |
|
This invention embodies synthetically produced, sustainable hydroisobenzofurans that kill cancer cells with high efficacy. |
 Annual Sales Forecast for USA * | Innovation Status |
Idea |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
Development
Status |
Proprietary
Protection Status |
Concept
Score |
| Ultra Low |
$0 |
$26,000 |
$270,000 |
1 of 5
In Development
|
1 of 5
Potential for Protection
|
37 29 is
Average
|
| Low Support |
$350,000 |
$1.1 M |
$2.9 M |
| Medium Support |
$3.0 M |
$8.1 M |
$18.7 M |
| High Support |
$8.0 M |
$21.7 M |
$49.7 M |
Remaining Time & Cost to First Sale |
| Ultra High |
$15.4 M |
$40.6 M |
$93.4 M |
6-10 yrs
|
$10M-$50M
|
New Cancer Treatment: Synthethic Hydroisobenzofurans
- Sustainable, synthetic hydroisobenzofurans for cancer treatment
Final Decision Maker: Biotech Director of Cencer Research, Medical Center Director of Cancer Research,
This invention is a promising cure for a variety of forms of cancer including several types of leukemia and solid tumor cell lines. University scientists have developed a unique synthesis process to create beneficial anticancer compounds that are similar to those naturally occurring in shellfish and some other marine life. These specific compounds have not previously been investigated for anticancer or antibiotic applications. To date testing has shown inhibition of growth of 50% of cancer test cells in controlled laboratory settings. The benefits of synthetic production are a reliable, sustainable, affordable supply of a potentially effective cancer treatment compound.
| $10,000 for each treatment | Seeking: Purchase, Investment, Distribution, Manufacturing/R&D |
|
* Consumption sales forecast. Does not include "Random" events or "Inventory Fill". Forecast is for Year 1 for Large or Year 2 for Small Companies.
Forecast should be read as ..."With Low marketing support there is an 80% odds of achieving sales of at least... |
| Listing #: USA.76.032509.002 |
Page 1 of 5 |
Date Posted: 2009-04-27 |
|
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Report Assumptions and Inventor(s) Commentary
|
|
| Inventor(s) Assumptions |
"Most Likely"
Estimate |
Confidence |
Inventor(s) Commentary
Data Source or Basis for Assumptions |
| # of Possible Final Decision Makers |
5,000 |
20% |
The estimates above include the number of R&D research universities in the US and account for the biotech and pharma companies focused on cancer research.
|
| Revenue per First Purchase |
$50,000.00 |
50% |
These are rough estimates based on possible pricing scenarios. |
| % that will Repeat |
75% |
50% |
The assumption is that cancer treatment might be required at regular intervals. |
| Number of Annual Repeats |
3 |
30% |
The treatment regime may vary once results from clinical trials are known. |
| Revenue per Repeat Purchase |
$50,000.00 |
30% |
These are early estimates as to the cost of treatments. |
| Reseller (Trade) Margin |
50% |
10% |
These are early estimates. |
| Producer Profit (EBITD) |
70% |
10% |
These are early estimates. |
| |
| Innovation Status |
|
Development
Status |
1 of 5
In Development
|
Hydroisobenzofurans or schleraphytes have been synthetically produced in the laboratory. Initial tests have shown strong results against solid tumor and lymphoma cell lines. |
| Cost to First Sale (remaining) |
$10M-$50M |
30% |
Given the many years of required FDA testing it is likely that at least $10M might be required to get this product ready for market. |
| Time to First Sale (remaining) |
6-10 yrs |
50% |
FDA approval cycles are very lengthy. |
| Confidence in Concept Claims made in description |
40% |
The efficacy against cancer cells has been tested both in University and NIH testing labs. |
Proprietary
Protection Status |
1 of 5
Potential for Protection
|
Currently the invention has not been publicly disclosed and the scientific details are closely held. The plan is to pursue patent protection. |
| Concept Score & Diagnostics |
|
|
| Concept Diagnostics |
Red |
Yellow |
Green |
| Percentile Group |
Bottom 40% |
Middle 40% |
Top 20% |
| Overt Benefit |
|
 |
|
| Reason to Believe |
 |
|
|
| Dramatic Difference |
|
|
|
|
| Listing #: USA.76.032509.002 |
Page 2 of 5 |
Date Posted: 2009-04-27 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Inventor Commentary & Alternative Development Scenarios
|
|
| Inventor(s) Sales Goals |
| Minimum Goal |
$5 M |
Current GOAL |
$10 M |
Technology made available through the University of Arkansas Technology Licensing Office. |
Inventor(s) Commentary:
This is a sustainable, repeatable way to synthetically produce rare anti-cancer compounds found in certain types of marine life. |
|
CURRENT SALES FORECAST |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$0 |
$26,000 |
$270,000 |
| Low Support |
$350,000 |
$1.1 M |
$2.9 M |
| Medium Support |
$3.0 M |
$8.1 M |
$18.7 M |
| High Support |
$8.0 M |
$21.7 M |
$49.7 M |
| Ultra High |
$15.4 M |
$40.6 M |
$93.4 M |
If MARKETING CONCEPT Improved (Increase Concept Score by +20 Points) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$0 |
$43,000 |
$420,000 |
| Low Support |
$550,000 |
$1.8 M |
$4.6 M |
| Medium Support |
$4.8 M |
$12.8 M |
$28.7 M |
| High Support |
$13.0 M |
$34.5 M |
$76.6 M |
| Ultra High |
$24.4 M |
$63.8 M |
$142.0 M |
If PRODUCT/SERVICE Improved (Increase Repeat Rate & Number of Repeats by 30% and Revenue Per Purchase 20%) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$0 |
$39,000 |
$430,000 |
| Low Support |
$500,000 |
$1.8 M |
$5.1 M |
| Medium Support |
$4.3 M |
$12.7 M |
$32.5 M |
| High Support |
$11.8 M |
$34.6 M |
$87.3 M |
| Ultra High |
$22.2 M |
$63.2 M |
$159.0 M |
If MARKETING CONCEPT and PRODUCT/SERVICE Improved (Increase Concept +20 Points, Repeat Rate & Number of repeats by 30% and Revenue per purchase 20%) |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$1 |
$62,000 |
$670,000 |
| Low Support |
$820,000 |
$2.7 M |
$7.8 M |
| Medium Support |
$7.0 M |
$19.9 M |
$50.4 M |
| High Support |
$18.8 M |
$52.9 M |
$137.0 M |
| Ultra High |
$35.2 M |
$103.1 M |
$253.3 M |
|
| Listing #: USA.76.032509.002 |
Page 3 of 5 |
Date Posted: 2009-04-27 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Additional Details
|
|
| Fair Market Royalty (%) |
| |
Conservative - 80% Odds
Royalty Percentage |
Most Likely - 50% Odds
Royalty Percentage |
Aggressive - 20% Odds
Royalty Percentage |
| At CURRENT State & Status |
5.1% |
7.3% |
10.1% |
Sales & Marketing
Support Level |
Annual Inventor Royalty Revenue |
3 Year Value
to Inventor
If 50% Odds |
| 80% Odds |
50% Odds |
20% Odds |
| Ultra Low Support |
$920 |
$2,800 |
$6,300 |
$8,300 |
| Low Support |
$15,000 |
$42,000 |
$87,000 |
$130,000 |
| Medium Support |
$110,000 |
$280,000 |
$570,000 |
$840,000 |
| High Support |
$280,000 |
$750,000 |
$1.5 M |
$2.2 M |
| Ultra High Support |
$530,000 |
$1.4 M |
$2.9 M |
$4.2 M |
| Sales & Marketing Support Level Assumptions |
| Sales & Marketing Support Level Assumptions |
Sample Numbers |
% Aware x
% Distribution
(Aware & Able) |
Inventor
Confidence |
| % Distribution |
% Awareness |
| Ultra Low Support (Word of Mouth) |
5% |
3% |
0.2% |
% |
| Low Support (Small Company) |
20% |
10% |
2% |
N/A |
| Medium Support (Medium Sized Company) |
50% |
25% |
13% |
N/A |
| High Support (Large Company) |
75% |
45% |
34% |
N/A |
| Ultra High Support (Mega or Niche) |
90% |
70% |
63% |
N/A |
|
Graph of EQUIVALENT (Awareness x Distribution) Combinations
 |
NAICS Industry Codes
For This Invention |
| 54171 - Research and Development in the Physical, Enginee... |
| |
| |
| |
| |
|
| Patent Numbers that apply to this Product/Service |
| |
| |
| |
| |
| |
|
| Inventor(s) PEDIGREE |
| Years EXPERIENCE in related industry |
15 |
| GRANTED Patents |
0 |
| Licensing Deals SIGNED |
0 |
| Innovations that have SHIPPED |
0 |
|
For USA Patents: Utility Patent = 7 digit number, Design Patent starts with D, Planet Patent starts with PP. Provisional Application "61/xxx,xxx", Non provisional application "12/xxx,xxx", Design patent application "29/xxx,xxx"
|
|
CAUTION: This Merwyn Business Simulation Research Report includes no warranty or guarantee. Results and opinions should be considered rough and directional in nature. This is because the report is based upon inventor-supplied data and simplified modeling methods. If you are looking to invest, distribute, purchase or become involved with this innovation, in any way, we strongly urge you to validate the inventor data and sales forecasts BEFORE committing yourself or your resources. Merwyn Research, Inc. shall not be responsible for any liability or damages arising out of the failure to perform such investigation and validation. Changes in the concept description, product, pricing, or input assumptions will almost certainly change results.
|
| Listing #: USA.76.032509.002 |
Page 4 of 5 |
Date Posted: 2009-04-27 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
Additional Forecasts for Other Countries
|
|
 Annual Sales - Probability Forecast - Canada |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$0 |
$4,200 |
$42,000 |
| Low Support |
$56,000 |
$180,000 |
$470,000 |
| Medium Support |
$470,000 |
$1.3 M |
$3.0 M |
| High Support |
$1.3 M |
$3.4 M |
$7.9 M |
| Ultra High |
$2.4 M |
$6.4 M |
$14.8 M |
 Annual Sales - Probability Forecast - United Kingdom |
Sales & Marketing
Support Level |
Conservative
80% odds
of selling |
Most Likely
50% odds
of selling |
Aggressive
20% odds
of selling |
| Ultra Low |
$0 |
$7,500 |
$75,000 |
| Low Support |
$99,000 |
$320,000 |
$830,000 |
| Medium Support |
$840,000 |
$2.3 M |
$5.3 M |
| High Support |
$2.3 M |
$6.1 M |
$14.0 M |
| Ultra High |
$4.3 M |
$11.4 M |
$26.3 M |
Forecast are calculated based on population, (PPP) purchasing power parity, International Trade, Urbanization and the Human Growth Index.
Forecast can be skewed for some industries, so for best results, adjusting the number of final decision makers for every country is recommended.
| Listing #: USA.76.032509.002 |
Page 5 of 5 |
Date Posted: 2009-04-27 |
| ©2008. Eureka! Institute. All Rights Reserved. Patents Granted or Pending Eureka! Ranch International www.EurekaRanch.com (513) 271-9911 |
|
